Scott Carlson

From OpenWetWare

(Difference between revisions)
Jump to: navigation, search
Current revision (00:17, 20 June 2010) (view source)
 
(41 intermediate revisions not shown.)
Line 1: Line 1:
-
I'm a first year PhD student in MIT's department of Bioengineering.  This content is questionable at best since I'm still figuring out the whole Wiki thing.  For now you can download my [http://web.mit.edu/scottmc/www/Scott_Carlson_CV.pdf CV].  Feel free to read whatever happens to be here.
+
<!-- CSS header information -->
 +
<div style="width: 800px;border: 3px solid #0000E9">
 +
<!-- Wiki header information -->
 +
__NOEDITSECTION__
 +
<!-- Document Body -->
 +
<nonwikionly>
 +
<font size='6'>Scott Carlson</font>
-
Skip to the [[User:Scottmc#Bio|Bio]] if you'd rather read my life story than my research.
+
</nonwikionly>
 +
<div style="padding: .0em .9em .9em">
 +
[[image:Scott_Carlson.png|220px|right]]
 +
{|
 +
|-
 +
__TOC__
 +
|}
 +
I'm a 5th-year graduate student in Biological Engineering at the Massachusetts Institute of Technology.  I work with Professor Forest White on phosphoproteomics applied to diabetes and cancer.
-
=Research=
+
=Research Interests=
-
==Protemics==
+
==Graduate Research==
-
==Biostatistics==
+
=== MAP kinases in cancer and diabetes ===
 +
The mitogen-activated protein kinases (MAPKs) are involved in signal transduction downstream of stress and growth factors.  Activation of JNK in a critical event in development of type II diabetes, and activation of ERK is involved in both diabetes and cancer.  I am combining mass spectrometry a chemical genetics strategy, developed by Kevan Shokat, to identify substrates of these kinases.
-
==Bioengineering==
+
=== Mechanisms of oncogenesis by KRAS mutation ===
 +
Activating mutations in KRAS occur in about 60% of all cancers.  The KRAS oncogene signals through several major pathways, including the Raf/MEK/ERK cascade.  This cascade is a major target for pharmaceutical research because of its importance in KRAS signaling and because it is targeted by other important oncogenes.  My goal is to understand how KRAS activation leads to cancer development by activating this and other pathways.
-
=Curriculum Vitae=
+
=== Regulation of alternative splicing ===
 +
Regulation of mRNA splicing is implicated in development of cancer, and especially in the progression to metastasis.  The splicing factor FOX2 is a global splicing regulator particularly important in development and frequently up-regulated in poorly differentiated cancers.  In collaboration with the Sharp Lab at MIT I am trying to understand how mitogenic and oncogenic signaling affects FOX2 activity.
-
=Comments?=
 
-
What's the point of a Wiki homepage if people don't make changes?  Add anything here (limit vulgarity of course)
+
==Undergraduate Research==
 +
===Clinical Proteomics===
 +
Using the combination of informatics and high-throughput experiments to identify clinically relevant diagnostics.  I worked with Dr. Harvey Cohen at Stanford to identify blood biomarkers for Kasawaki disease, monitor juvenile arthritis, and identify premature infants at risk for common disorders.
-
=Bio=
+
===Biostatistics===
-
Skip straight to [[User:Scottmc#Research]] if you don't feel like reading my life story
+
High-throughput experiments in proteomics and genomics have required a range of new statistical methods.  Protein measurements are often strongly correlated, and correlated variables interfere with most of the statistical analyses.  I applied clustering methods as a form of data-reduction to reduce problems introduced by correlated proteins.
-
I'm from Seattle WA, in the Pacific Northwest. In high school I picked up scientific interests in genetics and computational biology with Leonid Kruglyak at the Fred Hutchinson Cancer Research CenterAlong the way I got involved in politics, martial arts, and computer programming.
+
===Computational Genetics===
 +
I worked with Dr. Leonid Kruglyak and Dr. Elaine Ostrander on study of genetic variability among pure-breed dogs.  This work was published in Science (see the CV).
 +
 
 +
=iGEM=
 +
I'm a graduate student adviser for MIT's undergraduate team for the International Genetically Engineered Machines competitionSee the [http://2008.igem.org iGEM] website or our [[IGEM:MIT/2008|team wiki ]] for more information.
 +
 
 +
=Curriculum Vitae=
 +
Download my CV [http://web.mit.edu/scottmc/www/Scott_Carlson_CV.pdf here].
-
I finished undergrad in 2005 with a degree in Chemistry from Stanford.
+
</div>

Current revision

Contents

I'm a 5th-year graduate student in Biological Engineering at the Massachusetts Institute of Technology. I work with Professor Forest White on phosphoproteomics applied to diabetes and cancer.

Research Interests

Graduate Research

MAP kinases in cancer and diabetes

The mitogen-activated protein kinases (MAPKs) are involved in signal transduction downstream of stress and growth factors. Activation of JNK in a critical event in development of type II diabetes, and activation of ERK is involved in both diabetes and cancer. I am combining mass spectrometry a chemical genetics strategy, developed by Kevan Shokat, to identify substrates of these kinases.

Mechanisms of oncogenesis by KRAS mutation

Activating mutations in KRAS occur in about 60% of all cancers. The KRAS oncogene signals through several major pathways, including the Raf/MEK/ERK cascade. This cascade is a major target for pharmaceutical research because of its importance in KRAS signaling and because it is targeted by other important oncogenes. My goal is to understand how KRAS activation leads to cancer development by activating this and other pathways.

Regulation of alternative splicing

Regulation of mRNA splicing is implicated in development of cancer, and especially in the progression to metastasis. The splicing factor FOX2 is a global splicing regulator particularly important in development and frequently up-regulated in poorly differentiated cancers. In collaboration with the Sharp Lab at MIT I am trying to understand how mitogenic and oncogenic signaling affects FOX2 activity.


Undergraduate Research

Clinical Proteomics

Using the combination of informatics and high-throughput experiments to identify clinically relevant diagnostics. I worked with Dr. Harvey Cohen at Stanford to identify blood biomarkers for Kasawaki disease, monitor juvenile arthritis, and identify premature infants at risk for common disorders.

Biostatistics

High-throughput experiments in proteomics and genomics have required a range of new statistical methods. Protein measurements are often strongly correlated, and correlated variables interfere with most of the statistical analyses. I applied clustering methods as a form of data-reduction to reduce problems introduced by correlated proteins.

Computational Genetics

I worked with Dr. Leonid Kruglyak and Dr. Elaine Ostrander on study of genetic variability among pure-breed dogs. This work was published in Science (see the CV).

iGEM

I'm a graduate student adviser for MIT's undergraduate team for the International Genetically Engineered Machines competition. See the iGEM website or our team wiki for more information.

Curriculum Vitae

Download my CV here.

Personal tools